Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of Rondecabtagene Autoleucel, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma

NCT05826535 is registered in ClinicalTrials.gov with Lyell Immunopharma, Inc. as lead sponsor.

NCT NCT05826535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05826535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of Rondecabtagene Autoleucel, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
Lead sponsor
Lyell Immunopharma, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 9, 2023
Completion date
June 30, 2031
Enrollment
270 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

large b-cell lymphoma, non-hodgkin lymphoma, refractory non-hodgkin lymphoma, relapsed non-hodgkin lymphoma